L Wei1, D C Allain2, M N Bernhardt2, J L Gillespie3, S B Peters4, O H Iwenofu5, H H Nelson6,7, S T Arron8, A E Toland2,3. 1. Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, OH, U.S.A. 2. Department of Internal Medicine, Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, U.S.A. 3. Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, U.S.A. 4. Department of Pathology, Division of Dermatopathology, The Ohio State University Wexner Medical Center, Columbus, OH, U.S.A. 5. Department of Pathology and Laboratory Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, U.S.A. 6. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, U.S.A. 7. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, U.S.A. 8. Department of Dermatology, University of California San Francisco, San Francisco, CA, U.S.A.
Abstract
BACKGROUND: Variants at the oculocutaneous albinism 2 (OCA2)/HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) locus have been associated with pigmentation phenotypes and risk of developing several types of skin cancer. OBJECTIVES: To evaluate OCA2/HERC2 locus variants for their impact on time to develop cutaneous squamous cell carcinoma (cSCC) in organ transplant recipients (OTRs) who are at elevated risk of developing cSCC. METHODS: Participants were solid OTRs ascertained from two centres (n = 125 and 261) with an average of 13·1 years of follow-up post-transplant. DNA was available for genotyping for all participants, in addition to medical records and questionnaire data. The Ohio State University study had a case-control design with prospective follow-up, and the University of California San Francisco study was a national cross-sectional survey with retrospective chart review. RESULTS: OCA2 variants rs12913832 and rs916977 were significantly associated with time to first cSCC post-transplant. OTRs homozygous for the brown-eye alleles of rs916977 (GG) and rs12913832 (AA) had significant delays of time to first cSCC post-transplant compared with individuals homozygous for the blue-eye alleles (hazard ratio 0·34, P < 0·001 and hazard ratio 0·54, P = 0·012, respectively). Both variants were highly associated with eye colour in the combined studies (P < 0·001). CONCLUSIONS: This study is the first to show an association between OCA2/HERC2 variants and time to first cSCC post-transplant. This may impact dermatological screening recommendations for high-risk populations.
BACKGROUND: Variants at the oculocutaneous albinism 2 (OCA2)/HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) locus have been associated with pigmentation phenotypes and risk of developing several types of skin cancer. OBJECTIVES: To evaluate OCA2/HERC2 locus variants for their impact on time to develop cutaneous squamous cell carcinoma (cSCC) in organ transplant recipients (OTRs) who are at elevated risk of developing cSCC. METHODS:Participants were solid OTRs ascertained from two centres (n = 125 and 261) with an average of 13·1 years of follow-up post-transplant. DNA was available for genotyping for all participants, in addition to medical records and questionnaire data. The Ohio State University study had a case-control design with prospective follow-up, and the University of California San Francisco study was a national cross-sectional survey with retrospective chart review. RESULTS:OCA2 variants rs12913832 and rs916977 were significantly associated with time to first cSCC post-transplant. OTRs homozygous for the brown-eye alleles of rs916977 (GG) and rs12913832 (AA) had significant delays of time to first cSCC post-transplant compared with individuals homozygous for the blue-eye alleles (hazard ratio 0·34, P < 0·001 and hazard ratio 0·54, P = 0·012, respectively). Both variants were highly associated with eye colour in the combined studies (P < 0·001). CONCLUSIONS: This study is the first to show an association between OCA2/HERC2 variants and time to first cSCC post-transplant. This may impact dermatological screening recommendations for high-risk populations.
Authors: Ravinder Gogia; Maxwell Binstock; Ryutaro Hirose; W John Boscardin; Mary-Margaret Chren; Sarah T Arron Journal: J Am Acad Dermatol Date: 2012-10-26 Impact factor: 11.527
Authors: Anthony L Cook; Wei Chen; Amy E Thurber; Darren J Smit; Aaron G Smith; Timothy G Bladen; Darren L Brown; David L Duffy; Lorenza Pastorino; Giovanna Bianchi-Scarra; J Helen Leonard; Jennifer L Stow; Richard A Sturm Journal: J Invest Dermatol Date: 2008-07-24 Impact factor: 8.551
Authors: Richard A Sturm; David L Duffy; Zhen Zhen Zhao; Fabio P N Leite; Mitchell S Stark; Nicholas K Hayward; Nicholas G Martin; Grant W Montgomery Journal: Am J Hum Genet Date: 2008-01-24 Impact factor: 11.025
Authors: Fan Liu; Mijke Visser; David L Duffy; Pirro G Hysi; Leonie C Jacobs; Oscar Lao; Kaiyin Zhong; Susan Walsh; Lakshmi Chaitanya; Andreas Wollstein; Gu Zhu; Grant W Montgomery; Anjali K Henders; Massimo Mangino; Daniel Glass; Veronique Bataille; Richard A Sturm; Fernando Rivadeneira; Albert Hofman; Wilfred F J van IJcken; André G Uitterlinden; Robert-Jan T S Palstra; Timothy D Spector; Nicholas G Martin; Tamar E C Nijsten; Manfred Kayser Journal: Hum Genet Date: 2015-05-12 Impact factor: 4.132
Authors: Harvind S Chahal; Yuan Lin; Katherine J Ransohoff; David A Hinds; Wenting Wu; Hong-Ji Dai; Abrar A Qureshi; Wen-Qing Li; Peter Kraft; Jean Y Tang; Jiali Han; Kavita Y Sarin Journal: Nat Commun Date: 2016-07-18 Impact factor: 14.919
Authors: Elliot D Blue; S Caleb Freeman; Marissa B Lobl; Dillon D Clarey; Rose L Fredrick; Ashley Wysong; Melodi Javid Whitley Journal: JID Innov Date: 2022-03-30